Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Li, Shanshan  [Clear All Filters]
2023
Xiao H, Wang S, Tang Y, Li S, Jiang Y, Yang Y, Zhang Y, Han Y, Wu X, Zheng L, et al. Absence of terminal deoxynucleotidyl transferase expression in T-ALL/LBL accumulates chromosomal abnormalities to induce drug resistance. Int J Cancer. 2023.
Xia X, Sui Y, Zhou J, Li S, Ma X, Jiang J, Yan Y. Augmenting mesenchymal stem cell therapy for osteoarthritis via inflammatory priming: a comparative study on mesenchymal stem cells derived from various perinatal tissue sources. Front Cell Dev Biol. 2023;11:1279574.
Liu S, Zhang T, Li S, Wu Q, Wang K, Xu X, Lu MZ, Shao R, Zhao W, Liu H. Biomimetic Nanobomb for Synergistic Therapy with Inhibition of Cancer Stem Cells. Small. 2023:e2206503.
Hu J, Zhao J, Wang C, Jia M, Su M, Li S. Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2023.
Wang W, Li X, Qin X, Miao Y, Zhang Y, Li S, Yao R, Yang Y, Yu L, Zhu H, et al. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity. Br J Haematol. 2023.
Li S, Feng T, Zhang Y, Shi Q, Wang W, Ren J, Shen G, Gu H, Luo C, Li Y. Lianhua Qingwen protects LPS-induced acute lung injury by promoting M2 macrophage infiltration. J Ethnopharmacol. 2023:117467.
Zou Y, Li S, Chen W, Xu J. Urine-derived stem cell therapy for diabetes mellitus and its complications: progress and challenges. Endocrine. 2023.